2 results
Approved WMOWill not start
Phase 2: To evaluate progression-free survival (PFS) as the primary efficacy measure of MLN1117 plus docetaxel versus docetaxel alone in patients with advanced NSCLC
Approved WMORecruiting
To show the protective value and to measure cost effectiveness of higher Ig dosing on progression of lung disease in PAD.